湖南启元律师事务所 关于湖南九典制药股份有限公司 2022年限制性股票激励计划 调整相关事项、作废部分限制性股票及第三个归属 期归属条件成就的 法律意见书 ·湖南启元律师事务所· HUNAN QIYUAN LAW FIRM 湖南省长沙市芙蓉区建湘路 393 号世茂环球金融中心 63 层 410000 电话：0731-82953778 传真：0731-82953779 网站：www.qiyuan.com 致：湖南九典制药股份有限公司 湖南启元律师事务所（以下简称"本所"）接受湖南九典制药股份有限公司（以 下简称 "九典制药"、"公司"）的委托，作为公司2022年限制性股票激励计划（以 下简称"本次激励计划"）的专项法律顾问，根据《中华人民共和国公司法》（以 下简称"《公司法》"）、《中华人民共和国证券法》（以下简称"《证券法》"）、 《上市公司股权激励管理办法》（以下简称"《管理办法》"）、《深圳证券交 易所创业板股票上市规则（2025年修订）》（以下简称"《上市规则》"）等有 关法律、法规、规章及规范性文件的规定，就公司本次激励计划授予价格调整（以 下简称"本次调整"）、作废部分限制性股票（以下简称"本次作废 ...

| 证券代码：300705 | 证券简称：九典制药 | 公告编号：2025-046 | | --- | --- | --- | | 债券代码：123223 | 债券简称：九典转02 | | 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 湖南九典制药股份有限公司（以下简称"公司"）于2025年5月29日召开的 第四届董事会第十一次会议、第四届监事会第七次会议，审议通过了《关于作废 部分限制性股票的议案》，根据公司《2022年限制性股票激励计划（草案）》（以 下简称"《激励计划》"或"本激励计划"）的规定和公司2022年第二次临时股 东大会的授权，董事会同意作废部分已授予但尚未归属的限制性股票共1.0976 万股。现将有关事项说明如下： 一、2022 年限制性股票激励计划已履行的相关审批程序 1、2022 年 3 月 7 日，公司召开第三届董事会第八次会议，审议通过了《关 于公司<2022 年限制性股票激励计划（草案）>及其摘要的议案》《关于公司<2022 年限制性股票激励计划实施考核管理办法>的议案》等议案。公司独立董事就本 激励计划相关议案发表了独立意见。 ...

2、2022 年 3 月 7 日，公司召开第三届监事会第八次会议，审议通过了《关 于公司<2022 年限制性股票激励计划（草案）>及其摘要的议案》《关于公司<2022 年限制性股票激励计划实施考核管理办法>的议案》以及《关于公司<2022 年限 制性股票激励计划授予激励对象名单>的议案》，公司监事会对本激励计划的事 项进行核实并出具了相关核查意见。 3、2022 年 3 月 8 日至 2022 年 3 月 18 日，公司对本激励计划拟授予激励对 象的姓名和职务在公司官网进行了公示。在公示期内，公司监事会未收到任何人 对本次拟激励对象名单提出的异议。2022 年 3 月 18 日，公司于巨潮资讯网披露 了《监事会关于 2022 年限制性股票激励计划授予激励对象名单的核查意见及公 示情况说明》（公告编号：2022-018），《关于 2022 年限制性股票激励计划内 幕信息知情人买卖公司股票情况的自查报告》（公告编号：2022-019）。 关于调整 2022 年限制性股票激励计划相关事项的公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 湖南九典制药股份有限公司 ...

| 证券代码：300705 | 证券简称：九典制药 | 公告编号：2025-044 | | --- | --- | --- | | 债券代码：123223 | 债券简称：九典转02 | | 湖南九典制药股份有限公司 第四届监事会第七次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 湖南九典制药股份有限公司（以下简称"公司"）第四届监事会第七次会 议于 2025 年 5 月 29 日在公司 921 会议室以通讯会议方式召开，会议通知已于 2025 年 5 月 26 日以邮件方式送达。本次会议应出席的监事 3 人，实际出席的监 事 3 人，部分高级管理人员列席了会议，会议由监事会主席段斌女士召集并主持。 本次会议的召开符合有关法律、法规和《公司章程》的规定，形成的决议合法有 效。 二、监事会会议审议情况 1、审议通过了《关于调整 2022 年限制性股票激励计划相关事项的议案》； 经审核，监事会认为：公司对 2022 年限制性股票激励计划的相关事项调整 符合《上市公司股权激励管理办法》《2022 年限制性股票激励计划（草案）》 ...

Group 1 - Company Sun Energy plans to repurchase shares worth between 100 million to 200 million yuan for cancellation, with a maximum repurchase price of 6.69 yuan per share [1] - Company Runyang Technology intends to invest up to 300 million yuan in Shanghai Fourier Intelligent Technology Co., with a pre-investment valuation of 8 billion yuan [1] - Company Heng Rui Medicine's subsidiary has received approval for clinical trials of SHR-4712 injection for treating advanced solid tumors [2] Group 2 - Company Lianhuan Pharmaceutical plans to increase capital by 60 million yuan for its wholly-owned subsidiary [2] - Company Hongchang Electronics' subsidiary plans to increase capital by 10 million USD for its other subsidiary [2] - Company Sichuan Meifeng intends to repurchase shares worth between 50 million to 70 million yuan for cancellation, with a maximum repurchase price of 10.07 yuan per share [2] Group 3 - Company Lian Micro plans to liquidate and deregister Jiaxing Kangjing Semiconductor Industry Investment Partnership [4] - Company Jiutian Pharmaceutical has received approval for clinical trials of PDX-04 drug for treating acute gout attacks [5] - Company Pingzhi Information has signed a framework agreement with China Telecom for a GPU computing power project worth approximately 246 million yuan [7] Group 4 - Company Jiu Zhi Tang's subsidiary has initiated Phase II clinical trials for new drug YB211 aimed at treating acute bacterial skin infections [8] - Company Fosun Pharma's subsidiary has received orphan drug designation for HLX22 for gastric cancer treatment in the EU [9] - Company Jianyou Co. plans to repurchase shares worth between 20 million to 40 million yuan for employee stock ownership plans [11] Group 5 - Company Zhi Zheng Co. announced the resignation of its vice president due to personal reasons [13] - Company He Mai Co. signed a cooperation agreement for household photovoltaic systems worth 1 billion yuan [14] - Company Jinan Intelligent's subsidiary won a project bid for electric vehicle charging stations, expected to positively impact performance [16] Group 6 - Company Gaotie Electric plans to distribute a cash dividend of 0.012 yuan per share [18] - Company Guyue Longshan plans to distribute a cash dividend of 0.08 yuan per share [18] - Company Yongmaotai's shareholders plan to reduce their holdings by up to 2.66% of the company's shares [19] Group 7 - Company Tian Cheng Technology's subsidiary received a land idle fee notice for 2.1658 million yuan due to project delays [20] - Company Guangri Co. appointed a new vice president and board secretary to enhance governance [21] - Company Design General Institute won multiple major projects totaling approximately 390 million yuan [22] Group 8 - Company Fuxie Environmental signed a significant contract worth 244 million yuan for a sewage treatment project [23] - Company Lujiazui announced the resignation of its vice chairman due to job transfer [24] - Company Three Squirrels' H-share issuance application has been accepted by the CSRC [24] Group 9 - Company Kanghong Pharmaceutical's subsidiary received approval for clinical trials of KH617 for glioblastoma treatment [25] - Company Xin Zhu Co. announced a suspension of trading to plan an asset acquisition from its controlling shareholder [26] - Company Jianxin Co. announced plans for share reductions by several directors and senior management [28]

Core Viewpoint - The company has received approval from the National Medical Products Administration for clinical trials of a new drug, PDX-04, aimed at treating acute gout attacks, marking a significant development in its product pipeline [1] Group 1: Drug Development - PDX-04 is classified as a chemical drug of category 2.2 and is intended for use as a topical formulation [1] - The drug provides a new treatment option for patients suffering from acute gout attacks, a condition for which there are currently no similar products in clinical trials domestically or internationally [1] Group 2: Financial Impact - The approval for clinical trials of PDX-04 is not expected to have a significant impact on the company's financial status or operating performance [1]

| 证券代码：300705 | 证券简称：九典制药 | 公告编号：2025-042 | | --- | --- | --- | | 债券代码：123223 | 债券简称：九典转02 | | 湖南九典制药股份有限公司 关于公司获得药物临床试验批准通知书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 湖南九典制药股份有限公司（以下简称"公司"）于近日收到国家药品监督 管理局签发的《药物临床试验批准通知书》，在完成相关准备工作后将开展临床 试验研究。其相关信息如下： 一、临床试验通知书基本情况 药品名称：PDX-04 注册分类：化药 2.2 类 受理号：CXHL2500288、CXHL2500289（同产品不同规格） 申请人：湖南九典制药股份有限公司 拟定适应症：用于治疗痛风性急性发作镇痛。 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，2025 年 3 月 14 日受理的 PDX-04 符合药品注册的有关要求，同意开展痛风性急性发作 镇痛的临床试验。 二、同类药品的市场状况 PDX-04 用于治疗痛风性急性发作镇痛的药物，目前国内外未有该产 ...

Group 1: Company Overview and Strategy - The company focuses on mergers and acquisitions that align with its strategic development, aiming to enhance its supply chain, technology, market competitiveness, and product pipeline [2] - The company has established a comprehensive sales channel system, particularly in the outpatient market, which has become a new growth engine for performance [3] Group 2: Product Development and Market Potential - The company believes that the market for Loxoprofen Sodium Gel Patch in the outpatient sector has significant growth potential, supported by stable demand for topical patches in retail [4] - The company plans to continue investing in R&D to expand its product line and strengthen its brand "JiuYue" in the transdermal drug delivery field [3] Group 3: Competitive Positioning - Loxoprofen Sodium Gel Patch is a prescription drug effective for osteoarthritis and muscle pain, while the anti-inflammatory patch is an over-the-counter product with different ingredients and indications [5] - The company aims to leverage its complete supply chain to control costs and ensure product quality in response to competitive products gaining approval [2] Group 4: Financial Projections - For 2025, the company expects a revenue growth of 10-20% and a similar increase in net profit excluding non-recurring items [6] - The company warns that its operational plans and sales forecasts are subject to market conditions and other uncertainties, advising investors to remain aware of risks [7] Group 5: Marketing and Promotion Strategies - The company employs a multi-channel strategy for OTC promotion, integrating online and offline channels, and enhancing consumer experience through educational activities [7] - The brand "JiuYue" is positioned to meet diverse consumer needs through differentiated marketing and a varied product portfolio [7]

关于九典转 02 恢复转股的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 | 证券代码：300705 | 证券简称：九典制药 | 公告编号：2025-041 | | --- | --- | --- | | 债券代码：123223 | 债券简称：九典转02 | | 湖南九典制药股份有限公司 1、债券代码：123223 债券简称：九典转02 2、转股期限：2024年3月21日至2029年9月14日 3、暂停转股时间：2025年5月19日至2025年5月23日 4、恢复转股时间：2025年5月26日 特别提示： 湖南九典制药股份有限公司（以下简称"公司"）因实施2024年度权益分派， 根据《湖南九典制药股份有限公司创业板向不特定对象发行可转换公司债券募集 说明书》相关规定，自2025年5月19日至2025年5月23日九典转02暂停转股，具体 内容详见公司于巨潮资讯网刊登的《关于实施2024年度权益分派期间九典转02 暂停转股的公告》（公告编号：2025-037）。 根据相关规定，自2024年度权益分派股权登记日后的第一个交易日（即2025 年5月26日）起九 ...

Core Viewpoint - The company has received a drug registration certificate from the National Medical Products Administration for Lidocaine Gel Patch, indicating a significant regulatory approval for a new product aimed at treating postherpetic neuralgia [1] Group 1: Product Details - The drug is named Lidocaine Gel Patch, classified as a Class 3 chemical drug [1] - The formulation is a patch with dimensions of 14cm x 10cm, containing 14g of gel and 700mg of Lidocaine per patch [1] - The product is specifically indicated for alleviating pain associated with postherpetic neuralgia and is suitable for use on intact skin [1]